Research Article

Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway

Sun Guangshun 1, Sun Guoqiang 1, Chen Xin 1, Kong Xiangyi 1, Zheng Wubin 1, Li Zhitao 1, Zheng Zhiying 3, Cao Hongyong 6, Lv Chengyu 1, Xia Yongxiang 2, and Tang Weiwei 2

1Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
2Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China
3Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu, China

Correspondence should be addressed to Cao Hongyong; caohongy6167@163.com, Lv Chengyu; lcy_1234@aliyun.com, Xia Yongxiang; yx_xia@njmu.edu.cn, and Tang Weiwei; 1243773473twww@sina.com

Received 27 November 2021; Revised 12 January 2022; Accepted 28 January 2022; Published 21 February 2022

1. Introduction

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver, accounting for more than 90% of primary liver tumors. Approximately 80% of patients diagnosed with liver cirrhosis will develop HCC [1]. Existing statistics indicate that HCC is the fifth most common tumor in the world, and it ranks second in the cause of tumor deaths in men [2]. Studies have shown that the five-year survival rate of HCC is only 18%, which is currently second only to the king of cancers, pancreatic cancer [3]. There are many factors that can lead to the occurrence of HCC, such as viral hepatitis (hepatitis B and C)/fatty liver. Current treatments for HCC include surgical resection, liver
transplantation, tumor ablation, transarterial therapies, and systemic chemotherapy. Among them, surgical treatment is the most important treatment for early-onset HCC [4]. Although there are so many treatments for HCC, the overall survival of patients is still unsatisfactory. Therefore, more innovative treatment methods need to be developed.

One of the difficulties of cancer treatment lies in its complex immune evasion mechanism, and one of the key mechanisms is the expression of multiple immunosuppressive ligands on the surface of cancer cells. The most representative ligand is programmed cell death 1 ligand 1 (PD-L1). PD-L1 can bind to the programmed cell death protein 1 (PD1) receptor on the surface of T cells, thereby inhibiting the proliferation of T cells and production and release of cytokines and its cytolytic activity. Therefore, blocking and inhibiting PD-L1 or PD1 can restore the immune activity of T cells to a certain extent and then restore the immune surveillance and immune attack on tumors [5, 6]. Currently, studies on PD-L1 and PD1 have attracted more and more attention. Multiple checkpoint blocking immunotherapy have been developed to treat a variety of cancers including HCC. According to a study in 2020, the PD-L1 monoclonal antibody atezolizumab combined with bevacizumab in the treatment of advanced HCC was significantly better than traditional sorafenib in terms of overall survival and progression-free survival [7], which gradually established the status of immune combined targeted therapy in the treatment of HCC.

Although a variety of checkpoint inhibition treatments have achieved impressive results, but clinically, factors such as PD1 monoclonal antibody resistance mean that these immunotherapies can only benefit a small number of patients. Therefore, the crosstalk between conventional and targeted anticancer therapies combined with checkpoint suppression therapies may lead to more effective combined treatments for cancer. In this study, we screened more than 800 kinds of FDA drug library and fortunately found that meloxicam (COX2 inhibitor) is a drug that can effectively inhibit the growth and proliferation of HCC cells, and its anticancer effect has been confirmed in a variety of cancers previously. Cyclooxygenase-2 (COX2) is a rate-limiting enzyme that is mainly involved in the synthesis of prostaglandin (PG). Past studies have shown that it is overexpressed in many cancers including HCC. And it is regarded as a potential anticancer target [8, 9]. There is already evidence that COX2 can be induced by hypoxia and other conditions. COX2 can promote cell growth and angiogenesis and also slow cell apoptosis [10, 11]. However, how and whether meloxicam plays a role in cancer-related immunity remains unclear, so this study will focus on this issue.

2. Methods and Materials

2.1. Drug Screening. The FDA drug library including meloxicam was purchased from Selleck Chemicals LLC (USA). The Cell Counting Kit-8 (CCK-8) test experiment was used to screen more than 800 drugs. YY8103 and Hep3B cells were used to first undergo the dosing and incubation process at 37°C.

2.2. Cell Cultures. In the study, YY8103, Hep3B, and Hep1-6 cells were cultured in DMEM medium (BI, USA), which also contained 10% fetal bovine serum (FBS) (Gibco, USA), 5% streptomycin, and penicillin, incubated in a CO2 chamber at 37°C. Meloxicam comes from Horizon Corporation (Nanjing, China). The YY8103 and Hep3B cell lines used were treated with meloxicam at 10μM for 48 h. The cells obtained in this study were used in subsequent related experiments.

2.3. Transwell Assay. According to the manufacturer’s instructions, we inoculated processed YY8103 and Hep3B cells into 200 μL serum-free DMEM medium in the upper chamber. The transwell room (Corning, USA) accepted the paving process, used Matrigel mix (BD Biosciences, USA) for the invasion test process, and did not use the Matrigel mix for the migration test. DMEM medium and 10% FBS are introduced into the bottom chamber to become HCC cytochemical attractants. When the 48-hour incubation process is completed, the upper chamber is fixed and then stained with crystal violet (Kagan, China) for 15 minutes. For the visualization process, the cell line received the photo and counting process in three fields.

2.4. Wound Healing Assay. YY8103 and Hep3B cells undergo a drug treatment process when they are seeded on a 6-well culture plate. Using a standard 20 μl pipette tip can eliminate artificial linear wounds on a single layer of confluent cells. Remove free-floating cells and debris. Incubate the plate at 37°C in DMEM medium containing 10% FBS, 5% streptomycin, and penicillin. Record the width of the scratch under an inverted microscope, and then take pictures at 0, 24, and 48 hours.

2.5. Cell Proliferation Assay. We inoculated 1000 cancer cells in 96-well plates and treated them with 10 μL CCK-8 solution (RiboBio, China) at 0 h, 24 h, 48 h, and 72 h. According to the manufacturer’s instructions (Synergy, USA), cell absorbance is measured at various time points at 450 nm using a microplate reading element. We spread 5 × 10^4 cancer cells in 24-well plates and cultured the cells for 24 hours. Cell lines were incubated with a 50 mmol/L EdU solution for 2 h and fixed with 4% paraformaldehyde. According to the manufacturer’s agreement, cell lines were treated with Apollo Dye Solution and Hoechst SEAL. EdU cell lines were captured and counted under an Olympus FSX100 microscope (Olympus, Japan). During the plate clone formation experiment, the transfected cells were seeded in a 6-well plate at a density of 1000 cells per well, and then cultured in DMEM medium containing 10% FBS. After 10 days, the cells received a fixation based on the use of methanol and then stained with GIMSA. Finally, the colonies are imaged and counted.

2.6. COX2 Expression Level in Single Cells and Immune Analysis. The Human Protein Atlas database and TISCH database were used to analyze the expression of COX2 in
single liver cell and single HCC cell. The TISIDB database was used to analyze the correlation between COX2 expression and immune cells.

2.7. RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction (qRT-PCR). We used TRIzol reagent (Invitrogen, USA) to extract total RNA from precultured and transfected HCC cell lines. After induction and RNA quantification and quality testing, the total RNA was reverse transcribed into complementary DNA using the PrimeScript RT kit (Takara, China) under the recommended conditions. According to the manufacturer’s instructions, qRT-PCR was performed on an ABI 7500 instrument in triplicate. The primer sequences used in this experiment are: miR-200, miRNA-513, PD-L1, CD155, and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH is used to normalize mRNA expression levels, while U6 is used for miRNA.

2.8. Mice Model. The animal management committee of Nanjing Medical University approved the animal experiment, and all experiment procedures and animal caring conformed to the institutional ethics directions for animal-related experiments. We used 5-week-old male C57BL/6 mice to construct tumor xenograft models. The mice were randomly divided into 4 groups for intraperitoneal injection. The groups were PBS, meloxicam, anti-PD1, and meloxicam + anti-PD1 (n = 5 for the respective groups). 1 × 10^6 Hep1-6 cells were inoculated into right groin of C57BL/6 mice. A 5 mg/kg meloxicam intraperitoneal injection was made for the meloxicam group every four days. 10 mg/kg sorafenib was administered intraperitoneal injection for the sorafenib group every two days. The hepatic tumors were surgically removed on the eighth day and once per four days thereafter. After 16 days, the mice were killed, and the tumor tissue was taken out for weighing and immunohistochemical analysis.

2.9. Immunohistochemical Staining. Tumor tissues from mice were embedded in paraffin blocks for immunohistochemical staining and analysis. Tissue sections were deparaffinized and hydrated. Sections were incubated with 3% H2O2 for 10 min and then incubated at 4°C with primary antibodies (CD4, CD8, Ki67, COX2, PD1, and PD-L1) overnight. A secondary antibody was added and incubated at 37°C for 15 min. Tissue sections were stained using diaminobenzidine and hematoxylin. Finally, sections were dehydrated and covered with glass slides. All tissue sections were photographed using a microscope camera and analyzed using the TissueFAXS Viewer software program.

2.10. Statistical Analysis. The continuing information received the comparative analysis by performing one individual t-testing process of the two groups. A statistics-related analysis process was performed and presented graphically in GraphPad Prism 8.0. A P value of 0.05 was considered to be statistically significant.

3. Results

3.1. Pharmacologically Active Drug Screening Confirmed That Meloxicam Had Anti-HCC Activity. In order to screen new drugs with anti-HCC efficacy, we used the CCK8 method to determine more than 800 drugs against the YY8103 cell line, and finally determined that meloxicam had relatively good anti-HCC properties (Figure 1(a) and Supplementary Table 1). The chemical formula of meloxicam is shown in Figure 1(c). We screened the top six drugs with the best effects and tested their inhibitory effects on HCC cells at a level of 10 µM. We found that meloxicam had a relatively good performance (Figure 1(b)). We further compared the effects of meloxicam and the mainstream anti-HCC drug sorafenib on HCC cells at different concentration levels. The results showed that the performance of meloxicam was satisfactory (Figure 1(c)).

3.2. Meloxicam Effectively Inhibited the Proliferation, Migration, and Invasion of HCC Cells. In order to further verify the role of meloxicam in HCC cell lines, we added 10 µM meloxicam to the experimental group’s culture medium, and added the same amount of DMSO to the control group, and verified its effect through different assays. Scratch experiments confirmed that after adding 10 µM meloxicam, cell migration capabilities were significantly reduced (Figure 2(a)). The plate cloning experiment analysis and the result of CCK and the EUD assays show that the proliferation rate of HCC cell lines with 10 µM meloxicam was significantly reduced (Figures 2(c)–2(e)). In addition to the abovementioned experiments, we also performed the transwell experiment to verify the effect of meloxicam on the migration and invasion of HCC cell lines (Figure 2(b)). In summary, meloxicam could effectively inhibit the proliferation, migration, and invasion of HCC cells.

3.3. Expression Data of COX2 at the Single Cell Level of HCC. We used the Human Protein Atlas database and TISCH database to analyze single-cell level data of COX2 in the liver. The result indicates that COX2 is mainly expressed in Kupffer cells, hepatic stellate cells, endothelial cells, and T cells in the liver (Figures 3(a) and 3(b)). The TISCH database including LIHC_GSE125449_aPDL1aCTLA4, LIHC_GSE140228_10X, LIHC_GSE140228_Smartseq2, and LIHC_GSE98638 showed that in HCC, COX2 was mainly expressed in mast cells, mono/macro cells, and dendritic cells (DC) (Figure 3(c)). Those results indicated that COX2 might be associated with immune responses in HCC.

3.4. Expression of COX2 Was Correlated with Immune-Related Factors. Previous studies have confirmed the connection between tumor development and immune factors. We further explored the relationship between COX2 expression and some immune factors in different cancers using the TISIDB database. The result indicated that the expression of COX2 in spearman was associated with immuno-inhibitors, immunostimulators, and lymphocytes (Figures 4(a)–4(c)).
These results further indicated the potential effect of COX2 in the immune response.

3.5. Meloxicam Could Enhance the Expression of PD-L1 through Interaction with MicroRNA-200. In order to further explore the role of meloxicam in inhibiting the occurrence and development of HCC, we selected candidate genes PD-L1 and CD155 related to tumor immunity to explore the relationship between them. We used qRT-PCR to compare the expression of PD-L1 and CD155 on the surface of Hep3B and YY8103 cell lines after adding 10 µM meloxicam. To our surprise, the expression of PD-L1 instead of CD155 on the
Figure 2: Treatment of HCC cell lines with meloxicam could cause significant inhibitory effects on it. (a) The scratch test confirmed that meloxicam inhibited the invasion and metastasis ability of HCC cell lines. (b) After treatment with meloxicam, the migration and invasion of HCC cells were also inhibited. (c–e) The plate cloning experiment, the CCK8 experiment, and the EDU experiment confirmed that after treatment with meloxicam, the proliferation of HCC was effectively inhibited. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Western Blot further validated this result (Figure 5(c)). Studies have shown that the expression of PD-L1 on the cell surface is regulated by many factors. After consulting a large amount of literature, we chose microRNA-200 and microRNA-513 as testing objects. The qRT-PCR results indicated that after adding meloxicam in Hep3B and YY8103 cells, the expression of microRNA-200 was downregulated, and the correlation with the expression of microRNA-513 was not obvious (Figures 5(d) and 5(e)). Studies have confirmed that downregulation of microRNA-200 could upregulate the expression of PD-L1 in breast cancer [12], which suggested that meloxicam may regulate the expression of PD-L1 through its interaction with microRNA-200.
Figure 4: Continued.
### Figure 4: Correlations between COX2 expression and three cancer-related immunefactor types. (a) Correlation between COX2 expression and immunoinhibitors in HCC. (b) Correlation between COX2 expression and immunostimulator in HCC. (c) Correlation between COX2 expression and lymphocyte in HCC.

### Figure 5: Continued.
3.6. Meloxicam Combined with PD1 Monoclonal Antibody Could Inhibit the Growth of HCC In Vivo.

We used 5-week-old male C57BL/6 mice to construct tumor xenograft models. The mice were randomly divided into 4 groups, with five mice in each group. The control group was injected with 100 µl PBS intraperitoneally. The “meloxicam” group was intraperitoneally injected with meloxicam 5 mg/kg, and the “anti-PD1” group was intraperitoneally injected with PD1 monoclonal antibody 6.6 mg/kg. After 16 days, all mice participating in the experiment were sacrificed, and tumors were collected for size and weight measurement (Figure 6(a)). The results showed that compared with the control group, the meloxicam group/anti-PD1 group/combination group’s mice subcutaneous tumor volume was significantly reduced, and the weight was significantly reduced as well. Compared with the meloxicam group/anti-PD1 group, the subcutaneous tumor volume of mice in the combination group was significantly reduced and the weight was significantly reduced (Figures 6(b)–6(d)).

The results showed that compared with the PBS group, the meloxicam group significantly promoted the expression of CD8 and PD-L1, suggesting that the addition of meloxicam activated the immune function of HCC. When meloxicam was combined with anti-PD1, the expression of CD8 was significantly increased, and the expression of Ki-67, PD-L1, and PD1 was significantly decreased (Figures 7(a) and 7(b)). These differences suggested that the combination of meloxicam and PD1 monoclonal antibody had a strong therapeutic potential for HCC therapy in vivo. Finally, we drew a schematic showing that meloxicam inhibited HCC and increased the efficacy of anti-PD1 in the treatment of HCC (Figure 8).

4. Discussion

With the deepening of our research, we found that COX2 plays an important role in a variety of tumors, and it plays a role in different stages of tumorigenesis and development [13]. For example, COX2 is an inflammatory mediator of cancer and can inhibit the apoptosis of cancer cells [14–16]. COX2 participates in the formation of tumor blood vessels and can induce the activity of tumor stem cells [17–19].

Existing studies have found a variety of mechanism pathways to help COX2 achieve the abovementioned functions, including sirtuin (SIRT)/COX2 [20], NF-κβ/COX2 [21], COX2/STAT3 [22], PI3K/AKT/COX2 [23], COX-2/hypoxia inducible
Figure 6: Meloxicam combined with PD1 monoclonal antibody could inhibit the growth of HCC in vivo. (a) Mice model injection illustration. (b) Picture display of the respective group of tumors. (c) The tumor volumes were measured every 4 days. (d) The relative weights of tumors were evaluated. *** \( P < 0.001 \) and **** \( P < 0.0001 \).

Figure 7: Result of immunohistochemical analysis. (a, b) Immunohistochemical analysis showed that there were significant differences in the staining of CD4, CD8, Ki67, etc. between the control group and the combination group.
factor (HIF) [22], and other popular channels. The above-mentioned studies have confirmed the important role of COX2 in the occurrence and development of cancer. Our research also confirmed the anti-HCC effect of the COX2 inhibitor meloxicam through the screening of the FDA drug library.

As a popular antitumor chemotherapy regimen in recent years, PD1 has achieved satisfactory clinical results in the treatment of advanced HCC. However, the problems of PD1 monoclonal antibody resistance in further treatment have also triggered our thinking. Starting from the results of drug screening, we further confirmed the antitumor effect of meloxicam in animal experiments, especially the impressive therapeutic effect after combined with PD1 monoclonal antibody.

Previous studies have shown that microRNA-200 is a cell-autonomous inhibitor of epithelial-to-mesenchymal transition (EMT) and metastasis and can target PD-L1 to inhibit its expression. ZEB1 can activate EMT inhibited by microRNA-200 and break the targeting relationship between microRNA-200 and PDL1 [24]. Studies have confirmed that downregulation of microRNA-200 can upregulate the expression of PD-L1 in breast cancer [12]. In order to further explain the excellent therapeutic effect of meloxicam combined with PD1 monoclonal antibody on mouse HCC models, we discovered through a series of experiments that COX2 can interact with microRNA-200 to cause changes in PD-L1 levels. Our experimental results confirmed that after knocking down the expression of COX2, microRNA-200 in tumor cells decreased significantly, which may be a mechanism for meloxicam to upregulate the level of PD-L1.

Therefore, our experiments confirmed that meloxicam can inhibit the proliferation, invasion, and migration of different HCC cell lines. The novelty is that, for the first time, we screened meloxicam, a drug with strong anti-HCC potential, from 800 FDA-approved small-molecule drugs. We demonstrate for the first time that meloxicam remodels PD-L1 expression and enhances tumor immunotherapy sensitivity through the miR-200/PD-L1 pathway. We also demonstrated that in in vivo experiments in mice, meloxicam combined with PD1 monoclonal antibody is more effective than traditional monotherapy in the treatment of HCC, and it has a very strong clinical application potential for PD1-resistant patients. However, our experiment also has many imperfections. We did not use the patient-derived xenograft model to further verify our conclusions. At the same time, we did not co-culture the cancer cells used in the experiment with CD8+ T cells to more accurately simulate the HCC tumor microenvironment.
5. Conclusion
Meloxicam inhibits hepatocellular carcinoma progression and enhances the sensitivity of immunotherapy via the microRNA-200/PD-L1 pathway.

Data Availability
All the data are included within the article.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Guangshun Sun, Guoqiang Sun, Xin Chen, and Xiangyi Kong contributed equally to this work.

Supplementary Materials
In order to screen new drugs with anti-HCC efficacy, we used the CCK8 method to determine more than 800 drugs against the YY8103 cell line, and the experimental result is in Supplementary Table 1. (Supplementary Materials)

References
[1] G. N. Ioannou, M. F. Splan, N. S. Weiss, G. B. McDonald, L. Beretta, and S. P. Lee, "Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis," Clinical Gastroenterology and Hepatology, vol. 5, no. 8, pp. 938–945, 2007.
[2] J. Ferlay, I. Soerjomataram, R. Dikshit et al., "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012," International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.
[3] A. Jemal, E. M. Ward, C. J. Johnson et al., "Annual report to the nation on the status of cancer, 1975–2014, featuring survival," Journal of the National Cancer Institute, vol. 109, 2017.
[4] K. O. Asafo-Agyei and H. Samant, StatPearls, Treasure Island, FL, USA, 2021.
[5] G. J. Freeman, A. J. Long, Y. Iwai et al., "Engagement of the PD-1 immuno-inhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation," Journal of Experimental Medicine, vol. 192, no. 7, pp. 1027–1034, 2000.
[6] H. Dong, S. E. Strome, D. R. Salomao et al., "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion," Nature Medicine, vol. 8, no. 8, pp. 793–800, 2002.
[7] R. S. Finn, S. Qin, M. Ikeda et al., "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma," New England Journal of Medicine, vol. 382, no. 20, pp. 1894–1905, 2020.
[8] M. A. Kern, M. M. Schoneweiss, D. Sahi et al., "Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice," Carcinogenesis, vol. 25, no. 7, pp. 1193–1199, 2004.
[9] G. C. Leonardi, S. Candido, M. Cervello et al., "The tumor microenvironment in hepatocellular carcinoma (review)," International Journal of Oncology, vol. 40, pp. 1733–1747, 2012.
[10] J. R. Vane, Y. S. Bakhle, and R. M. Botting, "Cyclooxygenases 1 and 2," Annual Review of Pharmacology and Toxicology, vol. 38, no. 1, pp. 97–120, 1998.
[11] M. Tsuji, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R. N. DuBois, "Cyclooxygenase regulates angiogenesis induced by colon cancer cells," Cell, vol. 93, no. 5, pp. 705–716, 1998.
[12] M. Z. Noman, B. Janji, A. Abdou et al., "The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200," Oncoimmunology, vol. 6, no. 1, Article ID e1263412, 2017.
[13] N. Hashemi Goradel, M. Najafi, E. Salehi, B. Farhood, and K. Mortezaee, "Cyclooxygenase-2 in cancer: a review," Journal of Cellular Physiology, vol. 234, no. 5, pp. 5683–5699, 2019.
[14] S. J. Desai, B. Prickril, and A. Rasouly, "Mechanisms of phytonutrient modulation of cyclooxygenase-2 (COX-2) and inflammation related to cancer," Nutrition and Cancer, vol. 70, no. 3, pp. 350–375, 2018.
[15] F. Hosseini, A. Mahdian-Shabik, F. Jadii-Niaragh et al., "Anti-inflammatory and anti-tumor effects of a-l-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model," Biomedicine & Pharmacotherapy, vol. 98, pp. 793–800, 2018.
[16] H. Gungor, N. Ilhan, and H. Eroksuz, "The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer," Biomedicine & Pharmacotherapy, vol. 102, pp. 221–229, 2018.
[17] M. A. P. Monteuzuma, F. P. Fonseca, B. M. Benites et al., "COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma," Pathology, Research & Practice, vol. 214, no. 6, pp. 907–913, 2018.
[18] L. Jiang, Y. Wang, G. Liu et al., "C-Phycocyanin exerts anti-cancer effects via the MAPK signaling pathway in MDA-MB-231 cells," Cancer Cell International, vol. 18, no. 1, p. 12, 2018.
[19] C. Lu, A. Eskandari, P. B. Cressey, and K. Suntharalingam, "Cancer stem cell and bulk cancer cell active copper(II) complexes with vanillin Schiff base derivatives and naproxen," Chemistry-A European Journal, vol. 23, no. 47, pp. 11366–11374, 2017.
[20] D. K. Yadav, S. Kumar, S. Misra et al., "Molecular insights into the interaction of RONS and thieno[3,2-c]pyran analogs with SIRT6/COX-2: a molecular dynamics study," Scientific Reports, vol. 8, no. 1, p. 4777, 2018.
[21] M. P. Charalambous, C. Maihofner, C. Maihofner, U. Bambahra, T. Lightfoot, and N. J. Gooderham, "Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-κB and IκB kinase-α in human colorectal cancer epithelial cells," British Journal of Cancer, vol. 98, no. 10, pp. 1598–1604, 2003.
[22] P. Maturu, D. Jones, C. Ruteshouser et al., "Role of cyclooxygenase-2 pathway in creating an immunosuppressive microenvironment and in initiation and progression of Wilms' tumor," Neoplasia, vol. 19, no. 3, pp. 237–249, 2017.
[23] J. Chang, N. Tang, Q. Fang et al., "Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PISK/AKT pathway," Biochemical and Biophysical Research Communications, vol. 517, no. 1, pp. 1–7, 2019.
[24] L. Chen, D. L. Gibbons, S. Goswami et al., "Metastasis is regulated via microRNA-200/ZEBl axis control of tumour cell PD-L1 expression and intratumoral immunosuppression," Nature Communications, vol. 5, no. 1, p. 5241, 2014.